E-News Newsletter - May 2024
Annual Scientific Meetings
 



Alliance NCTN/NCORP/AFT at 2024 ASCO

The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene May 31-June 4, bringing together thousands of oncology professionals from around the world in person. This year's meeting theme is "The Art and Science of Cancer Care: From Comfort to Cure." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted.  

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance investigators will present more than 20 abstracts, sharing the latest findings on breast cancer, rare cancer, blood and bone cancer, GI and GU cancers, along with cancer control research. The Alliance will be well represented at this year's ASCO meeting.
 
Note that ASCO abstracts are embargoed until 5 pm ET Thursday, May 23. At that time, most of the abstracts will be released publicly to view. Until then, here are the abstract titles of studies Alliance researchers will present.

Breast Committee
Alliance A011502
Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502
First Author: Shipra Gandhi, MD
Rapid Oral Abstract  | Abstract # 11016
Learn about the trial here.

Alliance A011502
Correlation of stress, depression, sleep, and pain with race and body mass index (BMI): Secondary analysis from Alliance A011502
First Author: Shipra Gandhi, MD
Abstract # e23171 | online publication only
Learn about the trial here.

Experimental Therapeutics and Rare Tumor Committee
Alliance A091902
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS)
First Author: Juneko E. Grilley Olson, MD
Rapid Oral Abstract | Abstract # 11514
Learn about the trial here.

Alliance-EAY191-A6
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial
First Author: Ardaman Shergill, MD
Abstract # TPS4196 | Poster Board # 168a
Learn about the trial here.

AFT-50
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC)
First Author: Evelyn Cantillo, MD
Abstract # TPS5642 | Poster Board # 502b
Learn about the trial here.

Gastrointestinal (GI) Committee
Alliance A022101
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)
First Author: Eric D. Miller, MD, PhD
Abstract # TPS3633 | Poster Board # 294b
Learn about the trial here.

Alliance A022106
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
First Author: Erica S. Tsang, MD, MPH
Abstract # TPS4205 | Poster Board # 172b
Learn about the trial here.

Genitourinary (GU) Committee
Alliance A031201
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)
First Author: Susan Halabi, MD
Oral Session | Abstract # 5007
Learn about the trial here.

Alliance A032101
A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
First Author: Atish D. Choudhury, MD
Abstract # TPS5118 | Poster Board # 518b
Learn about the trial here.

AFT-19
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer
First Author: Ronald C. Chen, MD
Oral Session | Abstract # 5006
Learn about the trial here.

Lymphoma Committee
Alliance A051701
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701
First Author: Jeremy S. Abramson, MD
Rapid Oral Abstract  | Abstract # 7012
Learn about the trial here.

Neuro-Oncology Committee
Alliance A071401
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations
First Author: Priscilla Brastianos, MD
Oral Abstract Session | Abstract # 2001
Learn about the trial here.

Respiratory Committee
Alliance A082101
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101)
First Author: Aaron Mansfield, MD
Abstract # TPS8125 | Poster Board #382a
Learn about the trial here.

AFT-57
A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57)
First Author: Helen J. Ross, MD
Abstract # TPS8123 | Poster Board # 381a
Learn about the trial here.

Cancer Control Program
Prevention Committee
Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors
First Author: Jasmine S. Sukumar, MD
Abstract # e22541 | online publication only

Symptom Intervention Committee
Alliance A222001
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy
First Author: Brad J. Stish, MD
Oral Abstract Session | Abstract # LBA12004
Learn about the trial here.

Translational Research Program
Correlative Sciences
AFT-05
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13)
First Author: Otto Metzger, MD
Abstract # 538 | Poster Board # 130
Learn about the trial here.

Alliance A152001, CALGB-80405
Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405
First Author: Sandra Algaze, MD
Abstract # 3583 | Poster Board # 246
Learn about the trial here.

Alliance A152001, CALGB 80405
Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data
First Author: Karam Ashouri, MD
Abstract # 3145 | Poster Board # 290
Learn about the trial here.

Alliance A152001, CALGB 80405
Impact of GABA pathway genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance)
First Author: Francesca Battaglin, MD
Abstract # 3588 | Poster Board # 251
Learn about the trial here.

Alliance A152001, CALGB 80405
Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance)
First Author: Francesca Battaglin, MD
Abstract # 3144 | Poster Board # 289
Learn about the trial here.

Alliance A152001, CALGB-80405
Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration
First Author: Tadayoshi Hashimoto, MD
Abstract # 3548 | Poster Board # 211
Learn about the trial here.

Alliance A152001, CALGB 80405
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2
First Author: Joshua Millstein, MD
Abstract # 3523 | Poster Board # 186
Learn about the trial here.

 

Read more news briefs from this issue: